Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05038332 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Jan 15, 2024, no change to tracked fieldsv5-v7
  2. Eligibility criteria expanded, about 4 wordsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2021 to Nov 12, 2021
    • Site details revised
    v3
  4. Start date: Sep 2021 to Nov 2021
    • Primary completion date: Sep 2026 to Nov 2026
    • Study completion date: Sep 2029 to Nov 2029
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy \[SBRT\]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
Trial Details
NCT Number NCT05038332
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 136 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov